Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Mod GRF 1-29

CJC-1295 Without DAC

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Mod GRF 1-29 (CJC-1295 without DAC) is a synthetic GHRH(1-29) analog whose human evidence base is limited to short-term pharmacodynamic signals, meaning transient rises in growth hormone and IGF-1, rather than any clinical-outcome RCT. The two published healthy-adult trials in the Journal of Clinical Endocrinology and Metabolism (Teichman 2006 and Ionescu/Frohman 2006) both studied the long-acting DAC form, not the no-DAC form itself, so the no-DAC variant rests on inference from those and on preclinical and small combination studies. No controlled human trial has tested body composition, strength, or anti-aging endpoints for the no-DAC form, which keeps it at anecdotal/mechanistic evidence (grade 1).

FDA
Not approved; sold only as a research chemical. Evaluated for the 503A compounding bulks list and flagged for immunogenicity, aggregation, and impurity concerns; not an approved or compoundable drug.
WADA
Prohibited at all times under Section S2 (peptide hormones, growth factors, and related substances).

Reference only. Not medical advice.

What can go wrong

Unapproved research chemical; WADA-prohibited (S2); human data limited to short-term GH/IGF-1 signals from the DAC form; frequent injection; potential immunogenicity and unstudied long-term risk.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Mod GRF 1-29. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

CJC-1295 without the albumin-binding DAC. Shorter half-life, requiring more frequent dosing, but considered by some protocols to produce a more physiological GH pulse.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • GH optimization
  • Body composition

How it is supposed to work

Mod GRF 1-29 is a growth-hormone-releasing peptide, a close relative of Sermorelin built to last a little longer in the body. Like Sermorelin it tells the pituitary to release the body’s own growth hormone in a natural pulse, but four small changes to its structure protect it from the enzyme that breaks Sermorelin down within minutes, stretching its activity to around half an hour. It is used the same way the rest of this family is, in pulsed injections, usually paired with a second peptide that amplifies the same signal.

Mod GRF 1-29 is Sermorelin, the active 29-amino-acid core of growth-hormone-releasing hormone, with four amino-acid substitutions that resist enzymatic breakdown. It is commonly sold as CJC-1295 without DAC, which is the source of much confusion, because the better-known CJC-1295 with DAC carries an extra albumin-binding component that extends its half-life to about eight days. Mod GRF 1-29 has neither that component nor that duration.

Type
GHRH analog
Identity
Sermorelin, 4 substitutions
Half-life
About 30 minutes
Also called
CJC-1295 without DAC
Approved
No
Sport
Prohibited

The Short-Acting Middle Child Of The GHRH Analogs

Mod GRF 1-29 is best understood as the middle child of a single family, and most of what matters about it is covered in the Sermorelin and CJC-1295 entries. The three differ mainly in how long they last: Sermorelin clears in under ten minutes, Mod GRF 1-29 in roughly thirty, and CJC-1295 with the albumin-binding add-on for days. The short-acting versions are often described as more natural because they produce a brief pulse of growth hormone that then subsides, closer to the body’s own rhythm, while the long-acting one keeps growth hormone elevated in a way the body never does on its own. They share the whole family’s evidence picture and the whole family’s caution: stimulating growth hormone and the downstream growth factor that follows it is a recognized driver of cell proliferation, so the cancer-risk question hangs over all of them, none is approved for these uses, and all are prohibited in sport.

Safety in detail

Human evidence for the no-DAC form is limited to inferred short-term GH and IGF-1 pharmacodynamics; no controlled trial has tested clinical outcomes, and the FDA has associated the CJC-1295 class with immunogenicity and product-quality concerns.

  • It shares the growth-hormone family’s core concern: elevated growth hormone and downstream growth factor can promote cell proliferation.
  • It is not approved for these uses and is sold gray-market or compounded.
  • It is prohibited in sport.
  • Its specific risk profile rests on the broader GHRH-analog class rather than its own trials.

Children and teenagers

Mod GRF 1-29 has no validated pediatric use and is an unapproved injected peptide. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Mod GRF 1-29 reaches users through the same gray-market and compounding channels as the rest of the growth-hormone peptide family, often sold under the CJC-1295 name. There is no approved product for these uses. Its market is the body-composition and anti-aging peptide economy.

How we got here

Modified GRF 1-29 is a stabilized form of GHRH(1-29), the same 29-amino-acid fragment marketed as sermorelin, carrying four amino acid substitutions (positions 2, 8, 15, and 27) that resist enzymatic cleavage and extend its half-life to roughly 30 minutes. In bodybuilding and research supply channels it is commonly sold under the name CJC-1295 without DAC. It is distinct from the DAC-conjugated long-acting CJC-1295, which adds a Drug Affinity Complex tag to bind serum albumin and prolong action to days rather than minutes.

Mod GRF 1-29 came out of efforts to make Sermorelin, the active core of growth-hormone-releasing hormone, last longer, by substituting four amino acids for enzyme resistance. The further addition of an albumin-binding component produced the long-acting CJC-1295, leaving Mod GRF 1-29 as the short-acting form of the same molecule.

The numbers behind the grade

Type
GHRH analog
Identity
Modified Sermorelin
Half-life
~30 min
Approved
No
Sport
Prohibited
Evidence
Class-level

The people taking it

The short-acting middle child of the growth-hormone-releasing-hormone family, a stabilized Sermorelin often sold as CJC-1295 without DAC, sharing the whole family’s evidence and cancer-risk questions.

Mod GRF 1-29’s users are the body-composition and growth-hormone-optimization crowd, often stacking it with a releasing peptide, within the broader gray-market peptide community.

A short-acting GHRH analog sold gray-market for body composition and growth-hormone optimization, usually stacked with a releasing peptide, sharing the family’s class-level profile and cautions.

Set against the alternatives

Mod GRF 1-29 sits between Sermorelin, which is shorter-acting, and CJC-1295 with DAC, which lasts for days, and it is usually stacked with a growth-hormone-releasing peptide much as in the CJC-1295 plus ipamorelin combination covered elsewhere. Against Tesamorelin, the one approved member of this GHRH family, Mod GRF 1-29 is the unapproved, gray-market relative. Its identity is largely defined by where it falls on the family’s duration spectrum.

What we do not know

  • Whether the pulsatile short-acting versions are meaningfully safer than the long-acting one.
  • How the family’s growth-factor elevation affects long-term cancer risk.
  • Whether any of these unapproved uses would survive rigorous trials.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Mod GRF 1-29 is sold gray-market, often confusingly as CJC-1295, and shares the growth-hormone family’s unresolved cancer-risk question with no approval for these uses. Anyone weighing it should read the Sermorelin and CJC-1295 entries together, understand the DAC distinction so they know what they are actually buying, and treat the whole family as carrying the same class-level caution under medical guidance.

Gray-market research vials of unverified purity.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Mod GRF 1-29.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • GHRH-analog classestablished

    Like Sermorelin and CJC-1295, it binds the GHRH receptor to release the body’s own growth hormone in a pulse.

  • Half-life engineeringestablished

    Four amino-acid substitutions extend its activity from minutes to around half an hour, without the albumin-binding component of the long-acting version.

  • Shared concernsclass-wide

    It carries the growth-hormone family’s proliferation and cancer-risk questions and has no approval for these uses.